Patents matching “targeted”

US 9987377

Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells

EnGeneIC Molecular Delivery Pty Ltd · Granted Jun 5, 2018 · Expires May 31, 2038

US 9962448

Compounds and methods for targeted immune system delivery

Northwestern University · Granted May 8, 2018 · Expires May 3, 2038

US 9963700

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted May 8, 2018 · Expires May 3, 2038

US 9956293

Targeted therapeutics

Madrigal Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

US 9943604

Targeted therapeutic nucleosides and their use

Ionis Pharmaceuticals, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

US 9937207

Targeted disruption of T cell receptor genes using talens

Sangamo Therapeutics, Inc. · Granted Apr 10, 2018 · Expires Apr 5, 2038

US 9931412

Targeted theranostics

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 3, 2018 · Expires Mar 29, 2038

US 9925271

Targeted pharmacological chaperones

Marker Gene Technologies, Inc · Granted Mar 27, 2018 · Expires Mar 22, 2038

US 9914940

Targeted integration into the PPP1R12C locus

Sangamo Therapeutics, Inc. · Granted Mar 13, 2018 · Expires Mar 8, 2038

US 9889092

Low density lipoprotein nanocarriers for targeted delivery of omega-3 polyunsaturated fatty acids to cancer

The Board of Regents of the University of Texas System · Granted Feb 13, 2018 · Expires Feb 8, 2038

US 9878043

Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

EnGeneIC Molecular Delivery Pty Ltd · Granted Jan 30, 2018 · Expires Jan 25, 2038

US 9867785

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

EnGeneIC Molecular Delivery Pty Ltd · Granted Jan 16, 2018 · Expires Jan 11, 2038

US 9845346

Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

BIOMARIN PHARMACEUTICAL INC. · Granted Dec 19, 2017 · Expires Dec 14, 2037

US 9841426

Intracellular organelle peptide targeted enzyme substrates

Marker Gene Technologies, Inc · Granted Dec 12, 2017 · Expires Dec 7, 2037

US 9834787

Targeted integration into stem cells

Sangamo Therapeutics, Inc. · Granted Dec 5, 2017 · Expires Nov 30, 2037

US 9834587

Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

BIOMARIN PHARMACEUTICAL INC. · Granted Dec 5, 2017 · Expires Nov 30, 2037

US 9834588

Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

BIOMARIN PHARMACEUTICAL INC. · Granted Dec 5, 2017 · Expires Nov 30, 2037

US 9814762

Targeted therapeutic proteins

BIOMARIN PHARMACEUTICAL INC. · Granted Nov 14, 2017 · Expires Nov 9, 2037

US 9803021

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

The Regents of the University of California · Granted Oct 31, 2017 · Expires Oct 26, 2037

US 9789096

Methods and compositions for selective and targeted cancer therapy

The Board of Regents of the University of Texas System · Granted Oct 17, 2017 · Expires Oct 12, 2037

US 9782437

Methods and compositions for targeted cleavage and recombination

Sangamo Therapeutics, Inc. · Granted Oct 10, 2017 · Expires Oct 5, 2037

US 9771408

Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

BIOMARIN PHARMACEUTICAL INC. · Granted Sep 26, 2017 · Expires Sep 21, 2037

US 9771428

CD47 targeted therapies for the treatment of infectious disease

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 26, 2017 · Expires Sep 21, 2037

US 9744235

Treatment of cardiovascular disorders with targeted nanoparticles

The Board of Regents of the University of Oklahoma · Granted Aug 29, 2017 · Expires Aug 24, 2037